Financial statement report of 2021
1、 Financial statement report of 2021
(I) report overview
With the innovative technology independently developed as the core, the company develops gene sequencing products and services suitable for genetics and oncology, and develops a sequencing platform suitable for hospitals to independently carry out testing services (including sequencer, supporting reagents and analysis software). Fujian Herui Gene Technology Co., Ltd., a joint-stock subsidiary of the company, has entered the stage of commercial layout. At the same time, the company uses a comprehensive sequencing platform to provide high-quality scientific and technological services for scientific research institutions, colleges and universities and medical institutions at home and abroad. The company is actively expanding its business to include the analysis and application of gene big data and the transformation of data, constantly reserving testing services, constantly enriching the product line, actively arranging the genome database, continuing to establish a digital life science park and building a new gene industry ecosystem covering the four sectors of industry, science, research and capital under the background of the accelerated development of big data. The financial situation in the reporting period is as follows:
1. Operating results
On the revenue side, the company achieved an overall operating revenue of 1.422 billion yuan, a decrease of 7.67% over the same period last year. Among them, 1) the revenue from clinical business (medical testing services and Reagent Sales) was about 938 million yuan, a decrease of 6.90% over the same period of last year, mainly due to: 1) the price of product testing services in the mature stage of the company showed a downward trend, and the repeated covid-19 epidemic caused the number of hospital diagnosis and treatment to return to instability; 2) The company’s covid-19 testing service business in this period contracted compared with the same period last year.
2) The revenue from basic scientific research services was about 314 million yuan, a decrease of 24.08% over the same period of last year, mainly because the company provided solutions for basic scientific research customers (including but not limited to universities, research institutes and clinical institutions) with “personalized customized services”. With the conclusion of customers’ preliminary research projects, the procurement of phased scientific research services decreased.
3) The sales of equipment was about 116 million yuan, an increase of 42.48% over the same period of the previous year, mainly because the company nextseqcn500 (second-generation gene sequencing platform), as an ngs universal platform suitable for large-scale clinical gene testing, achieved strategic sales results of biotechnology companies in the field of Microbiology in this period.
4) The revenue from other businesses was about 52 million yuan, an increase of 45.23% over the same period last year, mainly due to the increase in the revenue from providing corresponding services to the outside world by virtue of the company’s technical strength and medical device registration experience.
On the cost side, the company’s overall operating cost increased by 7.70% over the same period last year, mainly due to: 1. The demand for testing services driven by covid-19 epidemic has led to a general rise in the prices of upstream testing raw materials; 2. Domestic and foreign trade turbulence and exchange rate fluctuations have led to instability in the price of equipment parts purchased overseas by the company.
On the expense side, due to the market layout and the implementation of equity incentive, the sales expenses and management expenses increased by 11.82% and 17.78% respectively over the same period of last year.
2. Assets and liabilities
1) The increased investment in the construction of Fujian Digital Life Industrial Park (phase I) (North District) led to a 33.60% decrease in monetary funds at the end of the period compared with the beginning of the year.
2) The company moderately increased the flow of loans and increased the efficiency of capital utilization. The short-term loans at the end of the period increased by 54.78% compared with the beginning of the year.
3) By the end of the period, the asset liability ratio of the company was 28.30%, and the overall asset liability level was low.
At present, the coverage rate of monetary funds to short-term loans is 219.32%. In the future, the company will gradually improve the efficiency of fund utilization and ensure the safety of funds.
3. Cash flow
The net cash flow from operating activities was 94 million yuan, a decrease of 41.71% over the same period of the previous year, mainly due to the increase in the sales of sequencer and supporting reagent and the increase in goods preparation and procurement.
To sum up, the company’s current financial situation reflects that in the post epidemic stage, the company has carried out reasonable expansion based on cash safety, steadily improved its business on the premise of ensuring operational safety, and the company’s underlying assets are relatively thick. In the future, the company will timely adjust its business strategy and actively improve its performance level.
(II) report specific data
1. Main accounting data of 2021
Change proportion of the project from 2021 to 2020
Operating income (yuan): 142218092129154038573247 – 7.67%
Net profit attributable to shareholders of listed company (yuan) -1108185628021066518877 -152.60%
Net cash flow from operating activities (yuan) 940314526516131007526 – 41.71%
Basic earnings per share (yuan / share) -0.3125 0.5941 -152.60%
Weighted average return on net assets -5.40%, 8.64% – 14.04%
Change proportion at the end of 2021 and 2020
Total assets (yuan): 351972182269324396920924 8.50%
Net assets attributable to shareholders of the listed company (yuan) 249019273355238843868250 4.26%
2. Financial position, operating results and cash flow
(I) financial status
(1) Asset status
At the end of 2021, the total assets of the company were 351972182269 yuan, an increase of 8.50% over the end of the previous year, of which the current assets decreased by 5.05% over the end of the previous year; Non current assets increased by 30.52% over the end of the previous year.
The main asset status and change reasons at the end of 2021 are as follows (unit: yuan):
Change range and reasons of the project at the end of 2021 and 2020
Current assets:
Sequencer and supporting reagent pin
Monetary capital 4178892950762930829894 – 34% increase in sales and increase in stock purchase
Caused by.
Other current assets 94691415395231925603 81% increase in input tax to be deducted
To.
Non current assets:
Fujian Digital Life Industrial Park
Construction in progress 267 Hunan Copote Science Technology Co.Ltd(600476) 663751814587033% (phase I) (North District) project
Due to the increase of construction investment.
Credit impairment loss and uncovered
Deferred income tax assets 63928111852635876701 142% deductible from making up losses
Temporary differences increase.
Prepaid Fujian digital life products
Other non current assets 270456855119 Jiangxi Selon Industrial Co.Ltd(002748) 16 42% increase in Park Engineering and decoration
Caused by the addition of.
(2) Liability status
At the end of 2021, the total liabilities of the company were 99601977026 yuan, an increase of 21% over the end of the previous year, of which the current liabilities increased by 38% over the end of the previous year; Non current liabilities decreased by 14% compared with the end of the previous year.
The main liabilities at the end of 2021 and the reasons for changes are as follows (unit: yuan):
Change range and reasons of the project at the end of 2021 and 2020
Short term borrowings 1905377914512310543903 55% increase in bank working capital loans
Caused by the addition of.
Accounts payable 3399289242324328765023 40% payable for sequencer and reagent, etc
Increased payment for raw materials.
Other payables 51814566012575219779 101% Fujian engineering construction deposit and
Due to the increase of government subsidies to be distributed.
(3) Owner’s equity status
At the end of 2021, the total owner’s equity of the company was 252370205243 yuan, an increase of 4% over the end of the previous year, of which the owner’s equity attributable to the parent company was 249019273355 yuan, an increase of 4% over the end of the previous year.
The main owner’s equity status and reasons for changes at the end of 2021 are as follows (unit: yuan):
Change range and reasons of the project at the end of 2021 and 2020
Phase I ESOP completed the non trading transfer of 445195141316041640495 – 72% of treasury shares subscribed for repurchased shares, resulting in the corresponding reduction of treasury shares corresponding to this part of shares.
(II) operating results
During the reporting period, the price of product testing services in the mature stage of the company showed a downward trend, and the superposition of covid-19 epidemic repeatedly made the number of hospital diagnosis and treatment unstable. At the same time, the company increased market expansion and internal incentive investment, resulting in the overall pressure on the short-term growth of the company’s performance. The changes of main income statement items in 2021 are as follows (unit: yuan):
Change range of the project from 2021 to 2020
Operating income 142218092129154038573247 – 8%
Operating cost 7859737362972975711225 8%
Sales expenses 3288309188729407086277 12%
Administrative expenses 1651971958514025889559 18%
R & D expenses 1282289332112579613798 2%
(III) cash flow status
The changes and causes of the main cash flow statement items in 2021 are as follows (unit: yuan):
Change range and reasons of the project from 2021 to 2020
4401201332 and 2019465730% of other operating activities were received, and 118% of them received cash collateral related to Fujian engineering construction
